Evidence map›Paper›PMID 41515196›Full record

ReviewNutrients2025

Nutraceutical Potential of Astaxanthin in Muscle Metabolism, Exercise Adaptation, and Obesity.

Juliana Silva Siqueira, Serena Castelli, Thiago Luiz Novaga Palacio, Gilda Aiello, Sara Baldelli, Alfonsina D'Amato, Alessandra De Bruno, Mauro Lombardo, Gianluca Tripodi

Abstract readReview
In one paragraph

Review in Nutrients, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Juliana Silva SiqueiraMedical School, São Paulo State University (UNESP), Botucatu 18618-687, Brazil.ORCID 0000-0003-3172-2199
Serena CastelliDepartment for the Promotion of Human Science and Quality of Life, San Raffaele Open University, Rome, Via di Val Cannuta, 247, 00166 Rome, Italy.ORCID 0000-0001-5857-8049
Thiago Luiz Novaga PalacioMedical School, São Paulo State University (UNESP), Botucatu 18618-687, Brazil.
Gilda AielloDepartment for the Promotion of Human Science and Quality of Life, San Raffaele Open University, Rome, Via di Val Cannuta, 247, 00166 Rome, Italy.ORCID 0000-0003-4327-0521
Sara BaldelliDepartment for the Promotion of Human Science and Quality of Life, San Raffaele Open University, Rome, Via di Val Cannuta, 247, 00166 Rome, Italy.ORCID 0000-0001-7003-3172
Alfonsina D'AmatoDepartment of Pharmaceutical Sciences, University of Milan, Via L. Mangiagalli 25, 20133 Milan, Italy.ORCID 0000-0002-8147-7235
Alessandra De BrunoDepartment for the Promotion of Human Science and Quality of Life, San Raffaele Open University, Rome, Via di Val Cannuta, 247, 00166 Rome, Italy.ORCID 0000-0001-5801-0752
Mauro LombardoDepartment for the Promotion of Human Science and Quality of Life, San Raffaele Open University, Rome, Via di Val Cannuta, 247, 00166 Rome, Italy.ORCID 0000-0001-7509-5487
Gianluca TripodiDepartment for the Promotion of Human Science and Quality of Life, San Raffaele Open University, Rome, Via di Val Cannuta, 247, 00166 Rome, Italy.ORCID 0000-0002-9079-0047

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Astaxanthin (AX), a naturally occurring xanthophyll carotenoid, has attracted growing scientific interest due to its potent antioxidant, anti-inflammatory, and metabolic-regulatory properties. This review provides a critical appraisal of the current evidence regarding the nutraceutical potential of AX in muscle metabolism, exercise adaptation, and obesity management. Preclinical and clinical findings indicate that AX enhances lipid utilization, promotes mitochondrial biogenesis through AMPK activation, and improves endurance and muscle strength, particularly among older adults. Moreover, AX mitigates exercise-induced oxidative stress and muscle damage, thereby supporting recovery and physiological adaptation. In obesity models, AX reduces adipose tissue inflammation, improves insulin sensitivity, and modulates adipokine secretion, suggesting a multifaceted role in metabolic syndrome prevention. Despite robust preclinical data, human trials remain limited and often yield inconsistent outcomes, highlighting the need for well-designed, long-term clinical studies. Emerging evidence highlights the importance of optimized delivery strategies to enhance AX bioavailability and mitochondrial targeting. Nanoemulsions, liposomes, and lipid-based carriers improve stability, absorption, and tissue distribution, thereby potentiating AX's effects on mitochondrial function and exercise adaptation. Overall, AX emerges as a promising nutraceutical candidate for enhancing muscle function, supporting exercise performance, and managing obesity-related metabolic disease, with delivery innovations representing a critical frontier for future translational applications.

Indexed as

Adaptation, PhysiologicalDietary SupplementsExerciseMuscle, SkeletalObesityAnimalsAntioxidantsHumansOxidative StressXanthophyllsAntioxidantsastaxanthineXanthophyllsastaxanthinformulation technologiesmuscle and exercise metabolismnutraceuticalsobesity

Identifiers

PMID41515196
PMCPMC12787713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.